BOSTON, Jan. 3, 2025 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular diseases, today announced that on December 31, 2024, the company granted equity awards to a new employee. , pursuant to the company’s 2024 Incentive Stock Incentive Plan, as incentive material for such new employee to begin working at the company according to Nasdaq. Listing Rule 5635(c)(4).
The employee received a total of 5,330 restricted stock units (RSUs). RSUs will vest in equal annual installments on the first four anniversaries of January 1, 2025, subject to such employee continuing service with the Company on each vesting date.
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular diseases with the potential to transform treatment from chronic management to single-course gene editing medicines. The company’s lead programs, VERVE-101, VERVE-102 and VERVE-201, target genes that have been widely validated as targets for reducing low-density lipoprotein cholesterol (LDL-C), one of the main causes of atherosclerotic cardiovascular disease (ASCVD). . VERVE-101 and VERVE-102 are designed to permanently disable the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be affected by low levels. elevated LDL-C. . VERVE-201 is designed to permanently disable the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have a high level of LDL-C despite treatment with maximally tolerated standard of care therapies and hypercholesterolemia. homozygous familial (HoFH). For more information, visit www.VerveTx.com.
Contact with investors
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
Source: Verve Therapeutics